Cargando…
High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
BACKGROUND: Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). AIM: This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its associati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore srl
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167402/ https://www.ncbi.nlm.nih.gov/pubmed/34042091 http://dx.doi.org/10.32074/1591-951X-217 |
_version_ | 1783701683874824192 |
---|---|
author | Sheta, Heba Abd El hafez, Amal Saif, Maha Elsergany, Alyaa R. Al emam, Doaa Abdelrazik, Mahmoud Mohamed |
author_facet | Sheta, Heba Abd El hafez, Amal Saif, Maha Elsergany, Alyaa R. Al emam, Doaa Abdelrazik, Mahmoud Mohamed |
author_sort | Sheta, Heba |
collection | PubMed |
description | BACKGROUND: Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). AIM: This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its association with clinico-pathological parameters in EOC including overall and disease-free survivals (OS, DFS) and patient’s outcome. METHODS: Patient’s socio-epidemiologic, clinical, radiological, laboratory, surgical, and follow-up data were collected. After histopathologic typing, grading and staging, FOXA1 IHC expression was scored in 98 EOC specimens. Clinico-pathological associations were investigated in high-and low-FOXA1 expression groups using appropriate statistical methods. Kaplan-Meier method was used for survival analysis. RESULTS: FOXA1 tumor cell nuclear staining was detected in 63.3% of EOC with weak, moderate and strong scores (28.6%, 12.2% and 22.5% respectively). Comparing high- and low-expression groups (34.7% and 65.3% respectively), high FOXA1 was associated with larger tumors, low mean serum CA-125, tumor histopathology (mucinous and low-grade serous), type I EOC, limited tumor’s anatomical extent, absence of nodal or distant metastases and omental nodules, earlier FIGO stages, non-recurrent tumors and survival advantage with longer and OS and DFS (all p ≤ 0.05). Independent predictors of high FOXA1 expression included: omental nodules, tumor’s anatomical extent and tumor’s size (p ≤ 0.001, = 0.046 and = 0.023 respectively). CONCLUSION: FOXA1 is frequently expressed in EOC notably mucinous and low-grade serous carcinomas in association with favorable prognostic clinico-pathological parameters and longer OS and DFS. It likely has a suppressor function in EOC and could be recommended as a prognostic and therapeutic biomarker. |
format | Online Article Text |
id | pubmed-8167402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Pacini Editore srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-81674022021-07-08 High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer Sheta, Heba Abd El hafez, Amal Saif, Maha Elsergany, Alyaa R. Al emam, Doaa Abdelrazik, Mahmoud Mohamed Pathologica Original Article BACKGROUND: Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). AIM: This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its association with clinico-pathological parameters in EOC including overall and disease-free survivals (OS, DFS) and patient’s outcome. METHODS: Patient’s socio-epidemiologic, clinical, radiological, laboratory, surgical, and follow-up data were collected. After histopathologic typing, grading and staging, FOXA1 IHC expression was scored in 98 EOC specimens. Clinico-pathological associations were investigated in high-and low-FOXA1 expression groups using appropriate statistical methods. Kaplan-Meier method was used for survival analysis. RESULTS: FOXA1 tumor cell nuclear staining was detected in 63.3% of EOC with weak, moderate and strong scores (28.6%, 12.2% and 22.5% respectively). Comparing high- and low-expression groups (34.7% and 65.3% respectively), high FOXA1 was associated with larger tumors, low mean serum CA-125, tumor histopathology (mucinous and low-grade serous), type I EOC, limited tumor’s anatomical extent, absence of nodal or distant metastases and omental nodules, earlier FIGO stages, non-recurrent tumors and survival advantage with longer and OS and DFS (all p ≤ 0.05). Independent predictors of high FOXA1 expression included: omental nodules, tumor’s anatomical extent and tumor’s size (p ≤ 0.001, = 0.046 and = 0.023 respectively). CONCLUSION: FOXA1 is frequently expressed in EOC notably mucinous and low-grade serous carcinomas in association with favorable prognostic clinico-pathological parameters and longer OS and DFS. It likely has a suppressor function in EOC and could be recommended as a prognostic and therapeutic biomarker. Pacini Editore srl 2021-04-01 /pmc/articles/PMC8167402/ /pubmed/34042091 http://dx.doi.org/10.32074/1591-951X-217 Text en © 2021 Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en |
spellingShingle | Original Article Sheta, Heba Abd El hafez, Amal Saif, Maha Elsergany, Alyaa R. Al emam, Doaa Abdelrazik, Mahmoud Mohamed High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
title | High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
title_full | High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
title_fullStr | High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
title_full_unstemmed | High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
title_short | High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
title_sort | high foxa1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167402/ https://www.ncbi.nlm.nih.gov/pubmed/34042091 http://dx.doi.org/10.32074/1591-951X-217 |
work_keys_str_mv | AT shetaheba highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer AT abdelhafezamal highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer AT saifmaha highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer AT elserganyalyaar highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer AT alemamdoaa highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer AT abdelrazikmahmoudmohamed highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer |